All Hail Biopharma Market Performance
Executive Summary
The first half of the year after a presidential election has meant losses for biopharma indices in the last three election cycles. On the heels of a year of strong performance for the sector, can momentum hold into 2013?
You may also be interested in...
More And Better Biotech IPOs, But Step-Ups Still Lag
Higher valuations, better quality companies, improved aftermarket performance and a broadening investor pool are all conspiring to advance the state of biotech IPOs. But VCs continue to see little step-up at IPO.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.